NEW YORK (GenomeWeb) – Biocept late on Monday priced its public offering of 8 million shares of its common stock and warrants to purchase up to 8 million shares of its stock. 

The combined offering price is $1.25 per share, the company said, adding the warrants have a per share exercise price of $1.56. The warrants are exercisable immediately and will expire five years from the date of issuance. Biocept anticipates gross proceeds of approximately $10 million from the offering. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.